AxoGen (NASDAQ:AXGN) Announces Quarterly Earnings Results

AxoGen (NASDAQ:AXGN) released its quarterly earnings data on Wednesday. The medical equipment provider reported $0.21 EPS for the quarter, beating the consensus estimate of $0.13 by $0.08, FiscalAI reports. The business had revenue of $75.83 million for the quarter, compared to the consensus estimate of $73.18 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%.

Here are the key takeaways from AxoGen’s conference call:

• Positive Sentiment: AxoGen reported third-quarter revenue of $75.8 million, up 26.2% year over year, with breast revenue increasing more than 60% and adjusted EBITDA rising 46% to $13.4 million. Management raised 2026 guidance to at least $290 million in revenue, including $7 million from BioCircuit, while maintaining expectations for at least 73% gross margin and positive free cash flow.
• Positive Sentiment: Commercial payer coverage for Avance reached approximately 96% of U.S. covered lives after Elevance removed its nerve-gap restriction and Aetna added coverage for certain upper-extremity repairs. The company said breast growth is supported by expanding account adoption, with roughly 485 active breast accounts and 590 active surgeons.
• Positive Sentiment: AxoGen completed its $200 million BioCircuit acquisition, adding NerveTape and access to direct nerve-repair procedures representing an estimated 40%–50% of transected nerve cases. Management expects the product to contribute to revenue growth and adjusted EBITDA margin in its first year, although integration and potential cannibalization risks remain.
• Negative Sentiment: Gross margin declined to 74.8% from 76.6% a year earlier and is expected to decrease sequentially in the fourth quarter as production shifts toward longer Avance grafts for breast procedures. The company also warned that BioCircuit purchase-accounting inventory adjustments could further pressure fourth-quarter and full-year gross margin, while higher amortization and administrative expenses are expected going forward.
• Positive Sentiment: AxoGen plans to begin prostate nerve-reconstruction market development in 2027 after treating more than 220 patients across 15 sites; among patients with at least six months of follow-up, surgeons reported better-than-expected erectile-function recovery in approximately 80% and pad-free urinary continence above expected levels in more than 95%. Prostate is not included in current guidance, but management views it as a potentially meaningful long-term growth driver.

AxoGen Stock Up 31.5%

AXGN opened at $49.25 on Thursday. The company has a fifty day moving average of $42.78 and a two-hundred day moving average of $39.28. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -72.43 and a beta of 1.17. AxoGen has a fifty-two week low of $18.46 and a fifty-two week high of $52.91. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Third-quarter earnings beat expectations: AxoGen reported adjusted earnings of $0.21 per share, above the $0.13–$0.14 analyst consensus and up from $0.12 a year earlier. Revenue rose to $75.83 million, exceeding estimates of approximately $73.18 million. AxoGen Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Full-year guidance was raised: Management now expects at least 29% revenue growth, or approximately $290 million in 2026 revenue. The increased outlook reinforces the market’s view that AxoGen is sustaining strong sales momentum. AxoGen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Investor momentum strengthened: Trading volume in AXGN call options surged, with 9,886 contracts purchased versus average daily volume of about 900. While options activity does not guarantee future gains, it signals heightened bullish speculation following the earnings release.
• Neutral Sentiment: Management commentary provided additional context: The earnings presentation and conference call are likely to receive close attention as investors assess the durability of growth and the company’s path toward consistent profitability. AxoGen Q3 2026 Earnings Call Transcript
• Negative Sentiment: Valuation and profitability risks remain: Despite the earnings beat, AxoGen continues to report a negative net margin and negative trailing price-to-earnings ratio. After the sharp rally, some market commentary questioned whether the stock’s improved outlook is already reflected in its price, increasing the risk of profit-taking or volatility.

Insider Activity

In related news, Director Kathy Weiler sold 14,150 shares of AxoGen stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $45.30, for a total value of $640,995.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of AxoGen stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total value of $3,195,450.00. Following the completion of the transaction, the executive vice president owned 50,135 shares of the company’s stock, valued at approximately $2,373,390.90. This represents a 57.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 98,503 shares of company stock valued at $4,656,947. Insiders own 2.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Morgan Stanley downgraded AxoGen to a “hold” rating in a research note on Tuesday, September 29th. HC Wainwright raised their target price on AxoGen from $53.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of AxoGen in a report on Wednesday. Finally, Barclays restated an “overweight” rating and issued a $60.00 price objective on shares of AxoGen in a research report on Thursday. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $55.55.

About AxoGen

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.